Purpose: We aimed to investigate the impact of anastrozole administration on the traditional components of the lipid profile (ie, total cholesterol [TC], LDL-C, HDL-C, and triglycerides [TGs]) by means of a systematic review and meta-analysis of randomized controlled trials.
Methods: We searched the PubMed/Medline, Scopus, Embase, and Web of Science databases for relevant randomized controlled trials published in the English language until January 18, 2022. The weighted mean difference (WMD) and 95% CIs were calculated using a random-effects model (DerSimonian and Laird methods).
Findings: Anastrozole administration significantly lowered TC concentrations when the treatment duration was ≤3 months (WMD = -2.73 mg/dL; 95% CI, -5.09 to -0.38 mg/dL; P = 0.02) and when the baseline TC concentration was ≥200 mg/dL (WMD = -3.64 mg/dL; 95% CI, -6.30 to -0.98 mg/dL; P = 0.007). HDL-C levels decreased after anastrozole administration when the treatment duration was >3 months (WMD = -1.67 mg/dL; 95% CI, -3.24 to -0.10 mg/dL; P = 0.03). Anastrozole administration had no impact on TG or LDL-C values.
Implications: Anastrozole administration in humans can decrease TC and HDL-C levels but has no effect on LDL-C or TG concentrations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinthera.2022.08.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of recombinant human growth hormone injection combined with Anastrozole on height and growth rate of adolescent idiopathic short stature and evaluation of adverse reactions.
Pak J Pharm Sci
January 2025
Department of Pediatrics, Changxing Peoples' Hospital Pediatrics, Huzhou, Zhejiang Province, China.
Recombinant human growth hormone (rhGH) injections combined with Anastrozole are increasingly used to treat adolescent idiopathic short stature (ISS), warranting further research. This study evaluated their effects on height, growth rate and adverse reactions in 72 adolescents with ISS treated at our hospital from December 2021 to December 2022. Patients were divided into a control group (rhGH alone) and a study group (rhGH + Anastrozole).
View Article and Find Full Text PDFEnhanced pharmacokinetic approach for anastrozole via macromolecule-based silk fibroin nanoparticles incorporated injectables for oestrogen-positive breast cancer therapy.
J Drug Target
January 2025
Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Mangalore, India.
Breast cancer (BC) is a substantial reason for cancer-related mortality among women across the globe. Anastrozole (ANS) is an effective orally administered hormonal therapy for oestrogen-positive (ER+) BC treatment. However, several side effects and pharmacokinetic limitations restricted the uses of ANS in BC therapy.
View Article and Find Full Text PDFCardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System.
Cancer Med
January 2025
Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, Georgia, USA.
Introduction: Emerging evidence suggests potential cardiovascular toxicities from oral endocrine therapies (ETs); however, results are conflicting. This study comprehensively examined adverse reactions of ETs and investigated cardiovascular and metabolic safety signals within the FDA Adverse Event Reporting System (FAERS).
Methods: Reports in the FAERS through December 2023 were analyzed for documented reactions to tamoxifen, letrozole, anastrozole, and exemestane in female breast cancer patients.
Selenium nano particles versus nano vitamin D3 in modulating anastrozole-induced osteoporosis on the mandibular alveolar bone of albino rats.
J Stomatol Oral Maxillofac Surg
December 2024
Associate Professor of Oral Biology, Faculty of Dentistry, Ain Shams University, Cairo, Egypt; Associate Professor of Basic Dental Sciences, Faculty of Dentistry, Ibn Sina University for Medical Sciences, Amman, Jordan.
Aim: Compare the efficiency of selenium nanoparticles (SeNPs) and Nano vitamin D3 in modulating alveolar bone osteoporosis induced by anastrozole in albino rats.
Materials And Methods: 28 female albino rats were randomly divided into 4 groups (7/group); Control group (GP I): rats were received distilled water orally. Anastrozole group (GP II): rats were orally given anastrozole (1 mg/kg/day) dissolved in distilled water.
Clinical validation of the suppressive impact of letrozole on liver fibrosis in patients with breast cancer undergoing continuous letrozole administration: A retrospective study.
PLoS One
October 2024
Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan.
Treatment strategies for preventing liver fibrosis have not yet been established. Letrozole, widely used for breast cancer, has recently been reported to suppress liver fibrosis in murine models. Therefore, we aimed to validate the suppressive effects of letrozole on liver fibrosis in the clinical setting.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!